Financial toxicity and its implication on quality of life in patients attending the palliative care department in a regional cancer centre: An observational study

IF 2 Q3 HEALTH POLICY & SERVICES Journal of Cancer Policy Pub Date : 2023-12-05 DOI:10.1016/j.jcpo.2023.100460
Vaishnavi Nikte , Savita Patil , Hemakshi Chaudhari , Chaitanya Patil , Reshma Pawar , Prasad Patil , Harshvardhan More , Ujjwal Katolkar
{"title":"Financial toxicity and its implication on quality of life in patients attending the palliative care department in a regional cancer centre: An observational study","authors":"Vaishnavi Nikte ,&nbsp;Savita Patil ,&nbsp;Hemakshi Chaudhari ,&nbsp;Chaitanya Patil ,&nbsp;Reshma Pawar ,&nbsp;Prasad Patil ,&nbsp;Harshvardhan More ,&nbsp;Ujjwal Katolkar","doi":"10.1016/j.jcpo.2023.100460","DOIUrl":null,"url":null,"abstract":"<div><p><span>In India the cancer burden for 2021 was 26.7 million disability-adjusted life years (DALYs), and this is expected to increase to 29.8 million in 2025 (Kulothungan et al., 2022). According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for one in six deaths. As per WHO, palliative care is a strategy that assists both adults and children along with their families in dealing with life-threatening illnesses. Currently, only 14% of those in need of pain and palliative (P&amp;P) care receive it globally (WHO, 2020). Financial toxicity (FT) is the term used to describe the negative effects that an excessive financial burden resulting from cancer have on patients, their families, and society (Desai and Gyawali, 2020). Addressing this gap will require significant adjustments to both demand- and supply-side policies to ensure accessible and equitable cancer care in India (Caduff et al., 2019). Measuring FT along with health-related </span>quality of life (HRQoL) represents a clinically relevant and patient-centred approach (de Souza et al., 2017).</p></div><div><h3>Aim and objective</h3><p>To estimate FT and its association with quality of life (QoL).</p></div><div><h3>Materials and methods</h3><p>This was an observational descriptive study conducted among cancer patients recommended for P&amp;P care. Scores were estimated from September 2022 to February 2023 using official tools: the Functional Assessment for Chronic illness Treatment Compressive Score for Financial Toxicity (FACIT-COST) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaires for Cancer (QLQ30).</p></div><div><h3>Results</h3><p>From 150 patients (70 males and 80 females, mean age 54.96 ± 13.5 years), 92.6% suffered from FT. Eleven patients (7.3%) were under FT grade 0, 41 (27.3%) were FT grade 1, 98 (65.3%) were FT grade 2, and no patients were under FT grade 3. At criterial alpha 0.05 (95%CI), FT and the global score for HRQoL showed an association. Among inpatient department (IPD) expenses, medication bills contributed the greatest expense at 33%, and among outpatient department (OPD) expenses treatment expenses contributed 50% of the total. Breast cancer (30 cases, 20%) and oral cancer (26 cases, 17.3%) were the most frequent cancers.</p></div><div><h3>Conclusion</h3><p>FT measured using the COST tool showed an association with HRQoL.</p></div><div><h3>Policy summary</h3><p>This paper refers to the insurance policies available for cancer patients irrespective of P&amp;P care treatment.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538323000772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

In India the cancer burden for 2021 was 26.7 million disability-adjusted life years (DALYs), and this is expected to increase to 29.8 million in 2025 (Kulothungan et al., 2022). According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for one in six deaths. As per WHO, palliative care is a strategy that assists both adults and children along with their families in dealing with life-threatening illnesses. Currently, only 14% of those in need of pain and palliative (P&P) care receive it globally (WHO, 2020). Financial toxicity (FT) is the term used to describe the negative effects that an excessive financial burden resulting from cancer have on patients, their families, and society (Desai and Gyawali, 2020). Addressing this gap will require significant adjustments to both demand- and supply-side policies to ensure accessible and equitable cancer care in India (Caduff et al., 2019). Measuring FT along with health-related quality of life (HRQoL) represents a clinically relevant and patient-centred approach (de Souza et al., 2017).

Aim and objective

To estimate FT and its association with quality of life (QoL).

Materials and methods

This was an observational descriptive study conducted among cancer patients recommended for P&P care. Scores were estimated from September 2022 to February 2023 using official tools: the Functional Assessment for Chronic illness Treatment Compressive Score for Financial Toxicity (FACIT-COST) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaires for Cancer (QLQ30).

Results

From 150 patients (70 males and 80 females, mean age 54.96 ± 13.5 years), 92.6% suffered from FT. Eleven patients (7.3%) were under FT grade 0, 41 (27.3%) were FT grade 1, 98 (65.3%) were FT grade 2, and no patients were under FT grade 3. At criterial alpha 0.05 (95%CI), FT and the global score for HRQoL showed an association. Among inpatient department (IPD) expenses, medication bills contributed the greatest expense at 33%, and among outpatient department (OPD) expenses treatment expenses contributed 50% of the total. Breast cancer (30 cases, 20%) and oral cancer (26 cases, 17.3%) were the most frequent cancers.

Conclusion

FT measured using the COST tool showed an association with HRQoL.

Policy summary

This paper refers to the insurance policies available for cancer patients irrespective of P&P care treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一家地区癌症中心姑息治疗部病人的财务毒性及其对生活质量的影响:一项观察性研究
在印度,2021年的癌症负担为2670万残疾调整生命年(DALYs),预计到2025年将增加到2980万(Kulothungan等人,2022年)。根据世界卫生组织(WHO)的数据,癌症是全球死亡的主要原因,占死亡人数的六分之一。根据世卫组织的说法,姑息治疗是一项帮助成人和儿童及其家人处理危及生命的疾病的战略。目前,在全球范围内,需要疼痛和姑息治疗的人中只有14%得到了治疗(世卫组织,2020年)。金融毒性(Financial toxicity, FT)是用来描述癌症造成的过度经济负担对患者、家庭和社会产生的负面影响的术语(Desai和Gyawali, 2020)。解决这一差距将需要对需求侧和供给侧政策进行重大调整,以确保印度的癌症护理可及性和公平性(Caduff等人,2019)。测量FT与健康相关生活质量(HRQoL)代表了一种临床相关和以患者为中心的方法(de Souza et al., 2017)。目的与目的评估FT及其与生活质量(QoL)的关系。材料和方法本研究是一项观察性描述性研究,研究对象为推荐进行P&护理的癌症患者。从2022年9月到2023年2月,使用官方工具估计得分:慢性疾病治疗功能评估财务毒性压缩评分(FACIT-COST)和欧洲癌症研究和治疗组织(EORTC)癌症生活质量问卷(QLQ30)。结果150例患者(男70例,女80例,平均年龄54.96±13.5岁)中,FT发生率为92.6%,FT 0级以下11例(7.3%),FT 1级41例(27.3%),FT 2级98例(65.3%),FT 3级无患者。在标准α 0.05 (95%CI)时,FT和HRQoL的总体评分显示出相关性。在住院部(IPD)费用中,医药费占33%,门诊(OPD)费用中,治疗费占50%。乳腺癌(30例,20%)和口腔癌(26例,17.3%)是最常见的癌症。结论使用COST工具测量的ft与HRQoL存在相关性。本论文是针对癌症患者在不考虑p&p护理治疗的情况下可获得的保险政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
期刊最新文献
Palliative Care in Turkey: Insights from experts through key informant interviews Is health-related quality of life sufficiently addressed in trials for breast cancer treatments? An assessment based on reimbursement opinions from the French health technology assessment body, 2009–2023 Shaping the future research agenda of Cancer Nursing in Italy: Insights and strategic directions Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients Artificial Intelligence and cancer: Profile of registered clinical trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1